The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Functional Gene Variants of CYP3A4
Abstract
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound–metabolizing enzyme in humans. Recently, increasing evidence has been found showing that variants in the CYP3A4 gene have functional significance and—in rare cases—lead to loss of activity, implying tremendous consequences for patients. This review article highlights the functional consequences of all CYP3A4 variants recognized by the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clinical Pharmacology & Therapeutics (2014); 96 3, 340–348. advance online publication 16 July 2014. doi:10.1038/clpt.2014.129
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T., Liehner, S., Saito, A., Ishiguro, N., Kishimoto, W., Ludwig-Schwellinger, E., Ebner, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042259 · Cited by 434
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360
Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29199-0 · Cited by 357
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Westlind, A., Löfberg, L., Tindberg, N., Andersson, T. B., & Ingelman-Sundberg, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0752 · Cited by 300
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Pan, Y.-Z., Gao, W., & Yu, A.-M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027680 · Cited by 272
Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165613 · Cited by 245
Identification and functional characterization of eight CYP3A4 protein variants.
Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan, E., Hustert, E., Zanger, U. M., Brockmöller, J., Klenk, H., Meyer, U., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00008 · Cited by 234
Novel mutations of CYP3A4 in Chinese.
Hsieh, K. P., Lin, Y. Y., Cheng, C., Lai, M., Lin, M., Siest, J.-P., & Huang, J. (2001) · PubMed · Cited by 186
CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS
Roy, J.-N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J., & Roger, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003822 · Cited by 182
Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population
Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., Kurose, K., Sai, K., Komamura, K., Ueno, K., et al. (2004) · Human Mutation · doi:10.1002/humu.9210 · Cited by 166
GONZALEZ, F. J., SCHMID, B. J., UMENO, M., MCBRIDE, O. W., HARDWICK, J. P., MEYER, U. A., GELBOIN, H. V., & IDLE, J. R. (1988) · DNA · doi:10.1089/dna.1988.7.79 · Cited by 164
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 162
Elens, L., van Schaik, R. H., Panin, N., Meyer, M. D., Wallemacq, P. E., Lison, D., Mourad, M., & Haufroid, V. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.90 · Cited by 154
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Klein, K., Thomas, M., Winter, S., Nussler, A. K., Niemi, M., Schwab, M. G., & Zanger, U. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.336 · Cited by 153
Lunde, I., Bremer, S., Midtvedt, K., Mohebi, B. U., Dahl, M., Bergan, S., Åsberg, A., & Christensen, H. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1656-3 · Cited by 136
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
García‐Martín, E., Martínez, C., Pizarro, R. M., Garcia-Gamito, F. J., Gullstén, H., Raunio, H., & Agúndez, J. A. G. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121371 · Cited by 136
Spurdle, A. B., Goodwin, B. J., Hodgson, E., Hopper, J. L., Chen, X., Purdie, D. M., McCredie, M. R. E., Giles, G. G., Chenevix‐Trench, G., & Liddle, C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00003 · Cited by 135
Westlind-Johnsson, A., HERMANN, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N., Zech, K., Ingelman‐Sundberg, M., & von Richter, O. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.015 · Cited by 128
Zeigler-Johnson, C. M., Friebel, T. M., Walker, A. H., Wang, Y., Spangler, E., Panossian, S., Patacsil‐Coomes, M., Aplenc, R., Wein, A. J., Malkowicz, S. B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1651 · Cited by 123
Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 116
Kajinami, K., Brousseau, M. E., Ordovás, J. M., & Schaefer, E. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.078 · Cited by 109
Elens, L., Hesselink, D. A., Bouamar, R., Budde, K., de Fijter, J. W., Meyer, M. D., Mourad, M., Kuypers, D. R. J., Haufroid, V., van Gelder, T., et al. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31829da6dd · Cited by 103
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
de Graan, A. M., Elens, L., Sprowl, J. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3786 · Cited by 101
Tseng, E., Walsky, R. L., Luzietti, R. A., Harris, J. J., Kosa, R. E., Goosen, T. C., Zientek, M. A., & Obach, R. S. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057000 · Cited by 95
Kang, Y., Park, S. Y., Yim, C., Kwak, H.-S., Gajendrarao, P., Krishnamoorthy, N., Yun, S.-C., Lee, K., & Han, K. M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.215 · Cited by 92
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
Eap, C. B., Buclin, T., Hustert, E., Bleiber, G., Golay, K. P., Aubert, A.-C., Baumann, P., Telenti, A., & Kerb, R. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0767-7 · Cited by 91
Qiu, X., Jiao, Z., Zhang, M., Zhong, L.-J., Hui-qi, L., Ma, C.-L., Zhang, L., & Zhong, M. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0520-8 · Cited by 89
Elens, L., Capron, A., van Schaik, R. H., Meyer, M. D., Pauw, L. D., Eddour, D. C., Latinne, D., Wallemacq, P. E., Mourad, M., & Haufroid, V. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318296045b · Cited by 88
Diekstra, M. H. M., Klümpen, H., Lolkema, M. P., Yu, H., Kloth, J. S. L., Gelderblom, H. A. J., van Schaik, R. H. N., Gurney, H., Swen, J. J., Huitema, A. D. R., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.47 · Cited by 80
Teft, W. A., Gong, I. Y., Dingle, B., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2511-4 · Cited by 80
Wang, A., Yu, B., Luo, C., Tan, Z., Zhou, G., Wang, L., Zhang, W., Li, Z., Liu, J., & Zhou, H. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0848-7 · Cited by 80
Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van Gelder, T., & van Schaik, R. H. N. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328351f3c1 · Cited by 77
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Garsa, A., McLeod, H. L., & Marsh, S. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-19 · Cited by 75
Shi, Y., Li, Y., Tang, J., et al. (2012) · Gene · doi:10.1016/j.gene.2012.10.048 · Cited by 67
Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control
Stockmann, C. R., Fassl, B. A., Gaedigk, R., Nkoy, F. L., Uchida, D. A., Monson, S., Reilly, C. A., Leeder, J. S., Yost, G. S., & Ward, R. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.11.031 · Cited by 66
Association of genotypes of the CYP3A cluster with midazolam disposition in vivo
Miao, J., Jin, Y., Marunde, R. L., Kim, S., Quinney, S. K., Radovich, M., Li, L., & Hall, S. D. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.21 · Cited by 66
Zhang, J., Zhang, H., Ding, X., Ma, S., & Miao, L.-Y. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1432-1 · Cited by 63
Miyazaki, M., Nakamura, K., Fujita, Y., Guengerich, F. P., Horiuchi, R., & Yamamoto, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021816 · Cited by 60
Elens, L., Nieuweboer, A. J. M., Clarke, S. J., Charles, K. A., de Graan, A. M., Haufroid, V., Mathijssen, R. H. J., & van Schaik, R. H. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.202 · Cited by 60
Kurzawski, M., Dąbrowska, J., Dziewanowski, K., Domański, L., Perużyńska, M., & Droździk, M. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.199 · Cited by 60
CYP3A4 Gene Polymorphisms Influence Testosterone 6β-hydroxylation
Murayama, N., Nakamura, T., Saeki, M., Soyama, A., Saito, Y., Sai, K., Ishida, S., Nakajima, O., Itoda, M., Ohno, Y., et al. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.150 · Cited by 58
Barratt, D. T., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L. L., Tuke, J., & Somogyi, A. A. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000032 · Cited by 55
van der Weide, K., & van der Weide, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000070 · Cited by 54
Gijsen, V. M. G. J., van Schaik, R. H., Elens, L., Soldin, O. P., Soldin, S. J., Koren, G., & de Wildt, S. N. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.80 · Cited by 53
Shi, X., Geng, F., Jiao, Z., Cui, X.-Y., Qiu, X., & Zhong, M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01206.x · Cited by 52
Analysis of CYP3A4 genetic polymorphisms in Han Chinese
Zhou, Q., Yu, X., Shu, C., Cai, Y., Gong, W., Wang, X., Wang, D.-M., & Hu, S. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.30 · Cited by 52
Characterization of the genetic variation present in CYP3A4 in three South African populations
Drögemöller, B. I., Plummer, M., Korkie, L., Agenbag, G., Dunaiski, A., Niehaus, D. J. H., Koen, L., Gebhardt, G., Schneider, N., Olckers, A., et al. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00017 · Cited by 49
Werk, A. N., Lefeldt, S., Bruckmueller, H., Hemmrich‐Stanisak, G., Franke, A., Roos, M., Küchle, C., Steubl, D., Schmaderer, C., Bräsen, J. H., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.210 · Cited by 46
Self-citationBaxter, S. D., Teft, W. A., Choi, Y., Winquist, E., & Kim, R. B. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2963-1 · Cited by 36
Shirasaka, Y., Chang, S. Y., Grubb, M. F., Peng, C.-C., Thummel, K. E., Isoherranen, N., & Rodrigues, A. D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049940 · Cited by 36
Willrich, M. A. V., Rodrigues, A. C., Cerda, Á., Genvigir, F. D. V., Arazi, S. S., Dórea, E. L., Bernik, M. M. S., Bertolami, M. C., Faludi, A. Á., Largura, Á., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.03.007 · Cited by 25
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
Kitzmiller, J. P., Sullivan, D. M., Phelps, M. A., Wang, D., & Sadée, W. (2013) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2012-0031 · Cited by 24
Assis, J., Pereira, D., Gomes, M. P., Marques, D. S., Marques, I., Nogueira, A., Catarino, R., & Medeiros, R. (2013) · Europe PMC (PubMed Central) · Cited by 22
Hu, M., Mak, V. W. L., Xiao, Y., & Tomlinson, B. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.181 · Cited by 19
Zhao, M., Luan, X., Cao, G., Liu, W., Xiong, J., Hu, G., Chen, R., Ning, R., Shang, W., Yang, J., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.010 · Cited by 17
Cited by
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Chang, S.-Y., Voellinger, J. L., Van Ness, K. P., Chapron, B., Shaffer, R. M., Neumann, T., White, C. C., Kavanagh, T. J., Kelly, E. J., & Eaton, D. L. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.01.007 · Cited by 49
Metadata
- Authors
- Werk, A. N., & Cascorbi, I.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-06-13
- Volume
- 96
- Issue
- 3
- Pages
- 340-348
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2080242218
- Cited by
- 273
- References
- 61
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.